Raloxifene: A Complete Guide for Postmenopausal Women

What Is Raloxifene?

Raloxifene is an oral, once-daily prescription medication classified as a selective estrogen receptor modulator (SERM). It was approved by the US Food and Drug Administration in 1997 for the prevention and treatment of postmenopausal osteoporosis, and again in 2007 for the reduction of invasive breast cancer risk in postmenopausal women at increased risk.^[1]

The original brand name is Evista, marketed by Eli Lilly. Following patent expiration in 2014, raloxifene became available as a generic in 60 mg tablets and is now the form most US patients receive. Generic and brand are therapeutically equivalent — the active ingredient, raloxifene hydrochloride, is identical.

Unlike traditional hormone replacement therapy (HRT), raloxifene is not a hormone. It is a non-steroidal molecule that interacts with the body’s estrogen receptors in a tissue-selective way, producing an estrogen-like effect in some tissues (such as bone) while blocking estrogen in others (such as breast and uterine tissue). This selectivity is what makes SERMs a distinct class of medication.

How Does Raloxifene Work? (Mechanism of Action)

Estrogen receptors are found throughout the body — in bone, breast tissue, the uterus, blood vessels, the brain, and elsewhere. Natural estrogens like estradiol activate these receptors, but the downstream effects depend on the cell type and the receptor subtype present.

Raloxifene binds to the same receptors but acts as either an agonist (activator) or an antagonist (blocker) depending on the tissue:

• Bone: raloxifene acts like estrogen, slowing bone resorption and helping preserve bone mineral density.
• Breast tissue: raloxifene blocks estrogen, reducing estrogen-driven cell growth — the basis for its breast cancer risk reduction.
• Uterine lining: raloxifene is largely neutral, neither thickening the endometrium (as unopposed estrogen would) nor causing breakthrough bleeding.
• Lipids: raloxifene modestly lowers LDL cholesterol, but it does not improve cardiovascular event rates.

This tissue-selective behavior is the central feature that distinguishes raloxifene from full estrogen replacement and from tamoxifen, the other SERM widely used in breast cancer prevention and treatment.

What Is Raloxifene Used For?

The FDA has approved raloxifene for two distinct indications, both restricted to postmenopausal women:

1. Prevention and treatment of postmenopausal osteoporosis

Raloxifene reduces the rate of bone loss after menopause and lowers the risk of vertebral (spine) fractures. The pivotal MORE (Multiple Outcomes of Raloxifene Evaluation) trial enrolled 7,705 postmenopausal women with osteoporosis and showed a significant reduction in new vertebral fractures over 3 years.^[2] The benefit on non-vertebral (e.g., hip) fractures was smaller and not statistically significant in most analyses.

2. Reduction of invasive breast cancer risk in postmenopausal women at increased risk

In high-risk postmenopausal women, raloxifene reduces the incidence of invasive breast cancer that is estrogen-receptor-positive. The CORE and STAR trials demonstrated meaningful risk reduction over years of continuous use, with raloxifene showing a more favorable uterine safety profile than tamoxifen, the comparator SERM.^[3][4]

Notably, raloxifene is not approved for treating existing breast cancer, for premenopausal women, or for menopausal symptom relief (hot flashes, night sweats, vaginal dryness). It is also not approved for cardiovascular disease prevention; in fact, the RUTH trial showed a small increase in fatal stroke risk in women with established coronary disease, although overall cardiovascular event rates were not significantly changed.^[3]

Raloxifene 60 mg: Why That’s the Standard Dose

Raloxifene is available in a single tablet strength: 60 mg, taken once daily. Clinical trials evaluated lower and higher doses; the 60 mg daily dose emerged as the optimal balance between meaningful bone-density and breast-cancer risk benefit and a manageable side-effect profile. Higher doses did not produce proportionally greater benefit but did increase certain side effects.

Raloxifene can be taken at any time of day, with or without food. Adherence — taking it consistently — is far more important than the specific time of day. Most women find that building the dose into an existing daily habit (such as morning coffee or evening tooth-brushing) helps with consistency.

If a dose is missed, take it as soon as you remember unless it is almost time for the next dose; do not double up. Long gaps in adherence reduce the cumulative benefit on fracture and breast cancer risk.

Raloxifene Hydrochloride (HCl) — What This Means

On a pharmacy bottle you will often see the medication labeled as raloxifene hydrochloride or raloxifene HCl. This is simply the pharmaceutical salt form of the active drug — pairing raloxifene with hydrochloric acid improves its stability and solubility for oral tablets. There is no clinical difference between raloxifene, raloxifene hydrochloride, and raloxifene HCl: they refer to the same medication. Both brand-name Evista and the FDA-approved generic versions are formulated as raloxifene HCl 60 mg.

Who Is a Good Candidate for Raloxifene?

Raloxifene is most often appropriate for postmenopausal women who:

• Have established osteoporosis or osteopenia with elevated fracture risk;
• Have an increased lifetime risk of invasive breast cancer (often estimated using the Gail or Tyrer-Cuzick risk models);
• Have both bone-loss concerns and an elevated breast cancer risk — the dual indication makes raloxifene particularly attractive in this group;
• Do not have active or past venous thromboembolism;
• Are not bothered by hot flashes severe enough to disrupt life (since raloxifene can worsen them);
• Prefer a non-hormonal approach, or have a personal or family history that argues against systemic estrogen therapy.

Who Should NOT Take Raloxifene

Raloxifene is contraindicated or generally avoided in:

• Premenopausal women — efficacy and safety have not been established and conception risk applies;
• Pregnant or potentially pregnant women — raloxifene is FDA Pregnancy Category X (known fetal harm);
• Women breastfeeding;
• Any history of venous thromboembolism: deep vein thrombosis, pulmonary embolism, or retinal vein thrombosis;
• Prolonged immobilization (post-surgical recovery, long-haul travel) — raloxifene should typically be paused;
• Concurrent use of systemic estrogen therapy;
• Severe hepatic impairment.

For a fuller discussion of contraindications, see raloxifene side effects and contraindications.

Common Side Effects: Quick Overview

The most commonly reported side effects in clinical trials and post-marketing use include:

• Hot flashes (especially in the first 6 months)
• Leg cramps and muscle aches
• Peripheral edema (swelling, usually mild)
• Flu-like symptoms
• Joint pain
• Sinus or throat irritation

The most clinically significant risk is venous thromboembolism — approximately a 2- to 3-fold increase over baseline, especially during the first 4 months of treatment. A full discussion of common, serious, and rare side effects is on the dedicated raloxifene side effects page.

Raloxifene vs Other Options: A Brief Comparison

Raloxifene sits in a small group of medications used to prevent osteoporotic fractures and reduce invasive breast cancer risk. Other relevant options include:

vs Tamoxifen (the other major SERM)

Tamoxifen and raloxifene have similar mechanisms in breast tissue, but tamoxifen is approved for both pre- and postmenopausal women, including for the treatment of hormone-receptor-positive breast cancer. The STAR trial directly compared the two in postmenopausal women at increased risk: both reduced invasive breast cancer, with raloxifene showing a more favorable safety profile for uterine cancer and clots. See raloxifene vs tamoxifen for details.

vs Bisphosphonates

Bisphosphonates such as alendronate (Fosamax), risedronate (Actonel), and zoledronic acid (Reclast) are first-line therapy for many postmenopausal women with osteoporosis. They generally produce larger improvements in bone density at the hip than raloxifene does, but they do not affect breast cancer risk. The right choice depends on fracture risk pattern, GI tolerance, and other factors.

vs Hormone Replacement Therapy (HRT)

HRT (estrogen alone, or estrogen plus progestogen) is highly effective for menopausal symptoms and bone protection, but it has a different risk-benefit profile, particularly for women with elevated breast cancer risk. Raloxifene is not interchangeable with HRT and is generally not the right tool for hot flashes. Other options for those exploring beyond raloxifene are discussed on the raloxifene alternatives page.

How Raloxifene Is Different from HRT

HRT and raloxifene are often discussed together because both can prevent bone loss in postmenopausal women, but they work very differently:

• HRT replaces hormones. Estrogen (with progesterone if the uterus is present) restores the hormonal environment of the premenopausal years. This addresses both menopausal symptoms and bone loss directly.
• Raloxifene mimics estrogen only in specific tissues. It improves bone density and reduces breast cancer risk but does not relieve hot flashes, vaginal dryness, or mood changes — and can sometimes worsen vasomotor symptoms.
• Risk profiles differ. HRT raises breast cancer risk modestly in some women but lowers fracture risk substantially and addresses symptoms. Raloxifene lowers breast cancer risk while protecting bone, but does not treat symptoms and carries clot risk.
• Ideal candidates differ. A 52-year-old woman with severe hot flashes and average breast cancer risk is usually better served by HRT. A 65-year-old woman with osteoporosis and a strong family history of breast cancer may be a textbook raloxifene candidate.

These are not stark either-or choices. The right medication depends on your full picture, and that is exactly the kind of nuanced conversation a hormone-trained provider is equipped to have.

What to Expect on Raloxifene

First weeks

Some women feel nothing different at all in the first weeks. Others experience hot flashes or mild leg cramps, especially within the first 1–3 months. These early side effects are generally not dangerous and often improve.

First six months

Most early side effects either resolve or become much milder. Hot flashes that persist beyond 6 months are worth discussing with your prescriber. Blood clot risk is highest during the first 4 months of treatment, so signs such as unexplained leg swelling, calf pain, sudden shortness of breath, or vision changes should prompt urgent medical attention.

Long-term (years)

Bone density improvement is gradual and confirmed on follow-up DXA scans, typically at 1- to 2-year intervals. The breast cancer risk-reduction benefit accumulates over years of continuous use. Side effects that remained mild in the first year tend to stay mild. Any new symptoms — particularly clot-related — should be discussed promptly.

Cost, Insurance, and Generics

Brand-name Evista is rarely necessary now that generic raloxifene HCl is available. Without insurance, a 30-day supply of generic raloxifene 60 mg typically costs between $15 and $50 at US retail pharmacies, and pharmacy discount programs can lower that further. Most insurance plans cover generic raloxifene with a modest copay.

Mail-order and 90-day fills usually reduce both cost and the friction of staying on therapy, which matters because the benefits of raloxifene are dose-dependent on actually taking it consistently over years.

Talking to Your Doctor About Raloxifene

Whether you are already on raloxifene or considering starting, useful questions to bring to your appointment include:

• “What is my actual bone density and 10-year fracture risk?” (FRAX score)
• “What is my breast cancer risk based on a validated model (Gail, Tyrer-Cuzick, etc.)?”
• “Given my risk profile, is raloxifene the best fit, or would HRT, a bisphosphonate, or tamoxifen serve me better?”
• “How are we going to monitor effectiveness — and what would prompt us to change course?”
• “What side effects should make me call you between visits?”

If your primary care provider has limited time to engage with these questions, you are not alone. Many women find that a telehealth consultation with a clinician specifically trained in women’s hormonal health offers the longer, more individualized conversation this category of medication deserves. These platforms can evaluate raloxifene specifically, but more importantly can compare it against all the options on the table — including HRT alternatives, bisphosphonates, lifestyle interventions, and ongoing monitoring strategies — and recommend a plan tailored to your numbers.